In our study, ALK-positive patients had a 6-month VTE incidence of 17.7%, which is similar to prior studies which demonstrated 6-month incidence of 15.7%-22.8%.18,23 In contrast to prior studies, the current study includes unselected NSCLC patients treated nationwide at both community-based and tertiary medical centers, improving the generalizability of these findings. Here, ALK is linked to non-small cell lung carcinoma.